Press Release Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights Aug 10
Press Release Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis Aug 5
Press Release Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aug 3